/ Capstone Therapeutics (OTCQB:CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and Principal Executive Officer, John Holliman, III. TheChairmansBlog.com is an exclusive online media ... 4 Traders, 4 days ago
SAVI Vital is an all-natural supplement based on the Mediterranean diet that helps to address cellular inflammation. The SAVI Health SAVI Health, a Utah company whose mission is to help people build their best life, is making it easier—and more ...PRWeb, 4 days ago
Capstone Therapeutics Announces Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals
TEMPE, Ariz., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Capstone Therapeutics ( OTCQB:CAPS ) ("the Company") and its joint venture affiliate, LipimetiX Development, LLC ("JV"), announced today the completion ofand results for its investigational AEM-28 (Apo ...Street Sweeper, 5 days ago Capstone Therapeutics (CAPS) Announces Phase 1b/2a Study Results For AEM-28 Showing Safety And Biomarker Efficacy Signals 12/16/2014 ClinicSpace, 5 days ago
In the holiday season, there's a lot of talk about the three wise men and the gifts they brought to the baby Jesus. In the Christmas Bible story, the three kings brought the Christ child gold, symbolizing his royalty, frankincense, symbolizing his ...Epoch Times, 6 days ago
Review Alexander Tenenbaum , Robert Klempfner and Enrique Z Fisman Cardiovascular Diabetology 2014, 13 :159 doi:10.1186/s12933-014-0159-y Published: 4 December 2014 Abstract (provisional) The existence of an independent association ...Cardiovascular Diabetology, 2 weeks ago
Isis Pharmaceuticals, Inc. Release: ISIS-APOCIII Rx Phase 2 Study In Patients With Familial Chylomicronemia Published In The New England Journal of Medicine
CARLSBAD, Calif. , Dec. 3, 2014 /PRNewswire/ --Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from a Phase 2 study of ISIS-APOCIII Rx in patients with familial chylomicronemia syndrome (FCS) were published in The New England ...BioSpace, 2 weeks ago ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine Crawford Financial Planning, 2 weeks ago
Amy J. Bidwell, Timothy J. Fairchild, Jessica Redmond, Long Wang, Stefan Keslacy, Jill A. Kanaley Disclosures Med Sci Sports Exerc.2014;46(11):2091-2098. Abstract and Introduction Abstract Objective This study aimed to determine the ...Diabetes Care, 3 weeks ago
Alnylam Pharmaceuticals : Presents New Pre-Clinical Data on RNAi Therapeutic Programs for Cardio-Metabolic Diseases at American Heart Association Scientific Sessions...
Alnylam Presents New Pre-Clinical Data on RNAi Therapeutic Programs for Cardio-Metabolic Diseases at American Heart Association Scientific Sessions 2014 By a News Reporter-Staff News Editor at Biotech Week -- Alnylam Pharmaceuticals, Inc.4 Traders, 3 weeks ago Alnylam reports favorable preclinical data from cardio-metabolic disease trials Individual.com, 3 weeks ago Alnylam Presents New Pre-Clinical Data on RNAi Therapeutic Programs for Cardio-Metabolic Diseases at American Heart Association Scientific Sessions 2014 Tamar Securities, 1 month ago Alnylam Pharmaceuticals Presents New Pre-Clinical Data On RNAi Therapeutic Programs For Cardio-Metabolic Diseases At American Heart Association Scientific Sessions 2014 BioSpace, 1 month ago
The Cobas 6000 Multipurpose Clinical Laboratory analyzer (Photo courtesy of Roche Diagnostics) Please add personal message for the request Please, fill the area above The relationship between apolipoprotein-B (Apo-B) concentration and the risk ...Lab Medica, 1 month ago
Amarin : Announces Presentation of MARINE and ANCHOR Analyses at the American Heart Association Scientific Sessions Showing Vascepa(R) Significantly Reduced Remnant-Like Particle Cholesterol in Hypertriglyceridemic Patients
BEDMINSTER, NJ and DUBLIN , IE -- (Marketwired) -- 11/17/14 -- Amarin Corporation Plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the ...4 Traders, 1 month ago Amarin Announces Presentation of MARINE and ANCHOR Analyses at the American Heart Association Scientific Sessions Showing Vascepa(R) Significantly Reduced Remnant-Like Particle Cholesterol in Hypertriglyceridemic Patients TradingCharts.com, 1 month ago
on your WebpageAdd Widget >Get your members hooked!